MOLECULAR TEMPLATES INC (MTEM)
US6085502085 - Common Stock
Which stocks are experiencing notable movement on Thursday?
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Which stocks are most active on Thursday?
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
These stocks are moving in today's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a...
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the second quarter ...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB...
7 F-Rated Penny Stocks to Avoid This June
These F-rated penny stocks have the lowest ratings from the Portfolio Grader based on factors like earnings, growth and momentum.
Molecular Templates, Inc. Provides Interim Update
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the first quarter o...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
MTEM stock results show that Molecular Templates beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Molecular Templates (NASDAQ:MTEM) just reported results for the fourth quarter ...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...